Participated · Seed · Mar 2023

123 Baby Box offers a monthly subscription box tailored to a child’s age and developmental stage, selected via a customer quiz and delivered across six product categories (health and wellness; development; playtime; useful items; “Mama’s goodies”; and special spotlights). Subscriptions are tiered at $59.99/month, $49.99/month for six months, and $39.99/month for an annual plan. The company provides manufacturers with customer insights, product-launch and advertising opportunities, and works with brands including Fisher-Price, Mattel, Nuby and Goddess Garden. Since launching in March 2021 the business grew 245%, tripled its revenue, and saw monthly recurring revenue increase fivefold over 2021. It secured a deal with a large U.S. breast pump distributor to send boxes to 1 million customers, expanded headcount by five to a total of nine employees, and operated out of the founder’s parents’ garage prior to fundraising. The company plans four revenue streams—the subscription box, an e-commerce store for individual products and a loyalty program, product-placement fees for manufacturers, and B2B sales for employee benefits—and will use new capital for a warehouse, marketing, hiring and inventory while targeting $100,000 MRR and $1M ARR.

Led · Series C · Apr 2022

OSF Digital is a global commerce and digital transformation leader that connects technology and strategy to drive business goals. Led by CEO Gerard (Gerry) Szatvanyi, the company serves large brands including L'Oréal, Burton Snowboards, Ubisoft and e.l.f. Cosmetics. OSF Digital has more than 1,800 employees and 49 offices worldwide and has been a Salesforce Partner for over ten years. The company raised USD 100M in Series C funding and intends to use the proceeds to accelerate service capability expansion, sales and marketing, industry-focused solutions, and mergers and acquisitions. Its clients span consumer goods, retail and education sectors. The company is headquartered in Quebec City, Canada. OSF Digital is a Canadian global commerce and digital cloud transformation company led by Gerard (Gerry) Szatvanyi. The firm provides enterprise Connected Commerce, order management (OMS), storefront management, CRM and cloud application development. It serves both B2C and B2B customers and helps businesses leverage commerce, marketing, sales and service solutions across the entire digital transformation journey. OSF has a presence in North America, Latin America, APAC and EMEA and works with brands including L’Oréal USA, Ubisoft, e.l.f. Cosmetics, Lush and others. In May 2021 the company received $43M in funding. The company intends to use the proceeds to support an acquisition roadmap to add new companies in 2021 that provide strategic services and solutions for its customers. OSF Commerce is a global leader in Salesforce Commerce Cloud and a Platinum Salesforce consulting partner that provides multi-cloud and B2B commerce solutions. The firm delivers technology, consulting, implementation and online shop management services and works with premier brands across North America, Europe and Asia, including Ubisoft, Bouclair, Geox, Kal Tire, Markwins Beauty and Urban Barn. OSF offers proprietary digital commerce innovations including OSF UnifyCOMMERCE (patent pending), which integrates customer data across Salesforce Clouds and multiple sales channels. The company has won Salesforce awards including the 2018 Lightning Bolt Trailblazer Award for Retail and Salesforce’s 2016 Partner Innovation Award in Retail. OSF reports over 120 ongoing projects and cites eight years of worldwide deployments and a longstanding partnership with Salesforce since 2009. With new capital, OSF plans to accelerate its commerce practice and expand global capabilities.

Participated · Series B · Aug 2021

Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company based in Hanover, Germany, developing non-coding RNA (ncRNA)-based therapeutics to prevent, repair and reverse diseases of the heart. Its lead candidate, CDR132L, is a highly stable oligonucleotide ncRNA inhibitor directed at micro‑RNA‑132 and has completed Phase 1b with a favorable safety profile and beneficial cardiac effects in 28 heart-failure patients. Cardior is initiating a Phase II trial of CDR132L with the aim of demonstrating clinical proof-of-concept as a disease-modifying therapy. The company’s approach seeks to block aberrant micro-RNA-132 levels to address cardiac hypertrophy, fibrosis, impaired contractility and reduced vascularization. Its pipeline addresses large cardiac indications as well as rare diseases such as hypertrophic and dilated cardiomyopathies. The company intends to use new funding to advance late-stage development of the lead program and expand its earlier-stage pipeline. Cardior Pharmaceuticals is a spin-off from Hannover Medical School advancing proprietary non-coding RNA technology to predict and treat heart failure. The company targets specific non-coding RNAs that simultaneously control cardiac growth and calcium handling/contractility of cardiomyocytes. Targeting these RNAs has been shown to reverse maladaptive cardiac remodeling and restore normal cardiac function. Cardior is led by CEO Dr. Claudia Ulbrich and CSO Prof. Thomas Thum. The company will use new funding to continue advancing its therapeutic programs.

Led · Equity · Jun 2021

MeetingPlay offers a proprietary software platform that creates rich attendee experiences across virtual, hybrid, and in-person events, emphasizing attendee-to-attendee and attendee-to-content connections. The platform includes features for attendee engagement, customized virtual environments, event attendance, and broadcast-quality programming. MeetingPlay serves numerous market-leading and Fortune 500 customers, including Marriott International, Databricks, and Autodesk. The company was founded in 2012 by co-CEOs Joe Schwinger and Lisa Vann and is described in the article as emerging as a market leader in event technology. MeetingPlay aims to transform the event industry by offering a single platform focused on forming meaningful connections during all phases of an event. MeetingPlay builds a proprietary software platform for virtual, in-person and hybrid events that emphasizes attendee engagement, customized virtual environments and broadcast-quality programming. Its product suite supports conferences, meetings and events with features for networking, content delivery and scalable broadcast experiences. The company serves enterprise clients including Marriott International, Databricks and Autodesk and says its platform can support audiences of 100,000 or more. Founded in 2012 and led by Co-CEOs Joe Schwinger and Lisa Vann, MeetingPlay positions itself as a market leader in hybrid event experiences. Through a new partnership with Sunstone Partners, MeetingPlay plans to fuel development of innovative products, expand delivery capabilities and enhance go-to-market strategies. The company reports unprecedented year-over-year growth, and the announced investment is intended to support aggressive growth, though detailed financial terms were not disclosed.

Participated · Equity · Sep 2020

Galecto is a clinical-stage biopharma focused on creating first-in-class treatments for cancer and liver diseases. Through its acquisition of Damora Therapeutics, Galecto has added a portfolio of antibody therapies that target mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs) such as Essential Thrombocythemia and Myelofibrosis. The lead asset, DMR-001, is a potentially best-in-class anti-mutCALR monoclonal antibody engineered for subcutaneous dosing and is expected to file an IND in mid-2026, with Phase 1 proof-of-concept data anticipated in 2027. Two additional antibodies, DMR-002 and DMR-003, are slated to enter Phase 1 studies thereafter. Galecto’s legacy pipeline also includes GB3226, a dual ENL-YEATS and FLT3 inhibitor being advanced toward an IND submission in Q1 2026 for acute myeloid leukemia. Following the $284.9 million private placement completed alongside the Damora acquisition, management projects a cash runway into 2029, sufficient to reach multiple clinical readouts. After conversion of the new preferred shares, Galecto will have 61,998,882 common shares outstanding.